NEWS

LATEST TROPIQ NEWS


MalDA prioritises malaria drug targets with TropIQ’s input

The Malaria Drug Accelerator (MalDA), of which TropIQ is part of, has put together a prioritisation of molecular targets against the malaria parasite Plasmodium falciparum. This publication further advocates target ...
Read more
/ News

Our team aids the discovery of a new anti-malarial scaffold.

Due to the continuing rise of resistances against commonly used medication, new anit-malarials are needed to combat the disease. This publication suggests Quinazolinone-2-carboxamide derivatives as a novel malaria drug. read ...
Read more
/ News

Review of MalDA’s scientific achievements just released

TropQI has been a part of The Malaria Drug Accelerator (MalDA) since 2018. This consortium consists of 17 research laboratories funded by the Bill and Melinda Gates foundation to advance ...
Read more
/ News

Our liver stage platform supports life cycle profiling for new anti-malarial.

In the battle against malaria new drugs are needed. This publication identified 1-(pyridine-4-yl)pyrrolidine-2-one derivates as a novel, dual stage active (asexual blood stages and liver stage), anti-malaria. read more here ...
Read more
/ News

TropIQ assists in life cycle profiling of genetically modified chimeric Plasmodium parasite.

To broaden the protective spectrum of a potential whole parasite vaccine against malaria, a chimeric P. falciparum parasite expressing P. falciparum and P. vivax circumsporozoite protein (csp) was generated. This ...
Read more
/ News

TropIQ Digitalises Its Discovery Platform with CDD Vault

CDD Vault will enable TropIQ Health Sciences to share research results with partners in real time Nijmegen and San Francisco October 8, 2020 TropIQ Health Sciences, a  biotechnology ...
Read more
/ News

TropIQ contributes to research on malaria vaccine

Production of the primary vaccine candidate Plasmodium falciparum circumsporozoite protein (PfCSP) has proven difficult. This publication for the first time presents a method to produce a soluble, full-length PfCSP which ...
Read more
/ News

Dr. Sheshachalam is joining TropIQ

Dr. Sheshachalam has joined the team as a Scientist. He is an experienced cell biologist with a broad expertise in immunology, molecular biology and drug discovery. He obtained his PhD ...
Read more
/ News

TropIQ CEO Koen Dechering gives radio interview on the new malaria drug candidate

Dutch national radio (BNR) has conducted an interview with TropIQ's CEO Koen Dechering on the recently published novel malaria drug candidate (see publication here). Listen to the interview here (in ...
Read more
/ News

TropIQ-led collaboration develops novel malaria candidate drug

A molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria. The antimalarial properties were revealed thanks to one researcher’s inspired hunch when the ...
Read more
/ News

TropIQ gains new Assistant Scientist

Mrs. De Bruijn is joining the Team as a Assistant Scientist with a wealth of experience in laboratory techniques in the fields of immunology, cell biology and molecular biology. She ...
Read more
/ News

TropIQ gains Business Administrator

Mrs. Bijsterveld is joining TropIQ as a Business Administrator with a strong background in financial management in various different fields of work. In her previous affiliations she acquired higher lever ...
Read more
/ News

TropIQ at the ICM Weekend School

TropIQ organised a science workshop at the IMC Weekend School. This is a supplementary school on Sundays for children (aged 10-14) from underprivileged neighbourhoods. Through a three-year course, professionals (volunteers) ...
Read more
/ News

New master student at the TropIQ

Ms. Sascha Bezemer is joining the team as our new intern. She is a biology master student with specialisation in health and disease. She is enrolled at Wageningen University and ...
Read more
/ News

TropIQ’s CSO, Robert Sauerwein knighted

Robert Sauerwein, CSO of TropIQ, receives a royal decoration for his pioneering work in malaria vaccinology and drug discovery. He receives the distinction of Knight in the Order of the ...
Read more
/ News

Scientist Dr. Youri van Nuland is joining the team

Dr. van Nuland is an experienced biochemist with a PhD from Wageningen University in the Netherlands. He is an expert in industrial biotechnology and previously worked on metabolic engineering of ...
Read more
/ News

New intern Tom Seijger starting

Mr. Seijger is an undergraduate student at the Saxion University of Applied Sciences in Enschede. He will be doing an internship contributing to projects involving malaria transmission. He will stay ...
Read more
/ News

Dr. Marnix Vlot is joining TropIQ as a postdoctoral scientist.

Dr. Vlot has earned his PhD in molecular microbiology at Wageningen University. He specialises in the molecular mechanism of the CRISPR-Cas gene editing system and will apply his skills to ...
Read more
/ News

Annemijn Grol joins the team.

Ms. Grol is an undergraduate student at the Avans University of Applied Sciences in Breda. She will be doing an internship contributing to our dengue project. She will stay with ...
Read more
/ News

TropIQ on national TV

As a reaction to TropIQs latest study preventing transmission of tropical diseases, published in PNAS in July this year, the Dutch television program EenVandaag (NPO1) presented an item on the ...
Read more
/ News